Table 4.

RR and 95% CI for preconception DAP concentrations and clinical outcomes among 522 women undergoing 785 IVF cycles.

		Implantation (273 women, 344 cycles)		Clinical pregnancy (237 women, 293 cycles)		Live birth (228 women, 282 cycles)
Exposure	Women (cycles)	Unadjusted	Adjusteda	Unadjusted	Adjusteda	Unadjusted	Adjusteda
DMP ($\mathrm{\mu }\mathrm{g}/\mathrm{g}$)
Q1 ($\le 0.38$)	131 (196)	Ref	Ref	Ref	Ref	Ref	Ref
Q2 (0.39–6.37)	130 (196)	1.09 (0.87, 1.37)	1.03 (0.83, 1.27)	1.02 (0.85, 1.24)	0.97 (0.81, 1.16)	1.03 (0.85, 1.24)	0.97 (0.81, 1.16)
Q3 (6.38–23.44)	131 (197)	0.94 (0.74, 1.20)	0.90 (0.72, 1.13)	0.98 (0.80, 1.20)	0.94 (0.78, 1.13)	0.96 (0.79, 1.17)	0.92 (0.77, 1.11)
Q4 ($\ge 23.45$)	130 (196)	0.92 (0.71, 1.19)	0.91 (0.71, 1.15)	0.96 (0.77, 1.19)	0.94 (0.77, 1.15)	0.99 (0.81, 1.22)	0.97 (0.80, 1.17)
$p$-trend	—	0.32	0.36	0.59	0.61	0.92	0.92
DMTP ($\mathrm{\mu }\mathrm{g}/\mathrm{g}$)
Q1 ($\le 0.79$)	131 (201)	Ref	Ref	Ref	Ref	Ref	Ref
Q2 (0.80–1.44)	131 (197)	0.92 (0.73, 1.16)	0.83 (0.67, 1.03)	0.94 (0.76, 1.15)	0.85 (0.70, 1.02)	0.98 (0.80, 1.20)	0.89 (0.74, 1.07)
Q3 (1.45–2.50)	130 (190)	0.97 (0.77, 1.23)	0.94 (0.75, 1.16)	1.09 (0.89, 1.33)	1.03 (0.86, 1.24)	1.09 (0.89, 1.32)	1.04 (0.86, 1.24)
Q4 ($\ge 2.51$)	130 (197)	0.92 (0.72, 1.17)	0.87 (0.70, 1.09)	1.01 (0.82, 1.24)	0.94 (0.79, 1.13)	1.04 (0.85, 1.26)	0.97 (0.81, 1.16)
$p$-trend	—	0.63	0.48	0.75	0.96	0.66	0.91
DEP ($\mathrm{\mu }\mathrm{g}/\mathrm{g}$)
Q1 ($\le 1.15$)	130 (196)	Ref	Ref	Ref	Ref	Ref	Ref
Q2 (1.16–9.76)	131 (196)	0.94 (0.76, 1.16)	0.89 (0.73, 1.08)	0.90 (0.76, 1.08)	0.88 (0.75, 1.03)	0.94 (0.79, 1.12)	0.92 (0.78, 1.08)
Q3 (9.77–41.30)	131 (197)	0.79 (0.62, 1.00)	0.80 (0.64, 0.98)	0.76 (0.62, 0.93)	0.78 (0.65, 0.93)	0.80 (0.65, 0.97)	0.81 (0.68, 0.97)
Q4 ($\ge 41.31$)	130 (196)	0.67 (0.52, 0.87)	0.69 (0.54, 0.87)	0.74 (0.60, 0.91)	0.76 (0.62, 0.92)	0.77 (0.63, 0.95)	0.79 (0.66, 0.96)
$p$-trend	—	0.004	0.005	0.02	0.02	0.02	0.04
DETP ($\mathrm{\mu }\mathrm{g}/\mathrm{g}$)
Q1 ($\le 1.01$)	131 (199)	Ref	Ref	Ref	Ref	Ref	Ref
Q2 (1.02–1.85)	131 (195)	1.13 (0.91, 1.40)	1.10 (0.89, 1.35)	1.15 (0.95, 1.39)	1.11 (0.93, 1.33)	1.17 (0.97, 1.40)	1.13 (0.94, 1.35)
Q3 (1.86–3.55)	130 (197)	0.83 (0.64, 1.07)	0.85 (0.68, 1.08)	0.90 (0.72, 1.12)	0.91 (0.75, 1.11)	0.90 (0.72, 1.11)	0.90 (0.74, 1.09)
Q4 ($\ge 3.56$)	130 (194)	0.89 (0.69, 1.14)	0.89 (0.71, 1.11)	0.96 (0.78, 1.18)	0.96 (0.80, 1.16)	0.96 (0.78, 1.18)	0.96 (0.80, 1.16)
$p$-trend	—	0.19	0.19	0.38	0.45	0.35	0.40
${\mathrm{\Sigma }}_4\text{DAP}$ (nmol/g)
Q1 ($\le 58.75$)	130 (197)	Ref	Ref	Ref	Ref	Ref	Ref
Q2 (58.76–240.70)	131 (195)	1.21 (0.98, 1.49)	1.08 (0.88, 1.32)	1.08 (0.90, 1.30)	0.99 (0.83, 1.17)	1.09 (0.91, 1.31)	1.01 (0.85, 1.19)
Q3 (240.71–592.02)	131 (197)	0.90 (0.70, 1.14)	0.83 (0.66, 1.05)	0.92 (0.75, 1.12)	0.86 (0.71, 1.04)	0.92 (0.76, 1.13)	0.87 (0.72, 1.05)
Q4 ($\ge 592.03$)	130 (196)	0.79 (0.60, 1.03)	0.77 (0.60, 0.99)	0.81 (0.65, 1.02)	0.80 (0.65, 0.99)	0.88 (0.71, 1.08)	0.86 (0.70, 1.05)
$p$-trend	—	0.01	0.02	0.02	0.03	0.09	0.10

Note: RR and 95% CI for preconception DAP concentrations and clinical outcomes were estimated using GEE models. —, no data; BMI, body mass index; CI, confidence interval; DAP, dialkylphosphate; DEP, diethylphosphate; DETP, diethylthiophosphate; DMP, dimethylphosphate; DMTP, dimethylthiophosphate; GEE, generalized estimating equations; IVF, in vitro fertilization; PSS, perceived stress scale; RR, risk ratios.

^aAdjusted for age, BMI, duration of infertility, smoking status, education, annual household income, infertility diagnosis, two items from the PSS-10 questionnaire (“Have you been upset because of something that happened unexpectedly?” and “Have felt unable to control the important things in your life?”).